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THE PHARMACEUTICAL FRONTIER:
EXTENDING GENERIC POSSIBILITIES TO
BIOLOGIC THERAPIES IN THE BIOLOGICS
PRICE COMPETITION AND INNOVATION ACT
OF 2007
I. INTRODUCTION
The modem generic drug industry is generally thought to have
been borne out of The Drug Price Competition and Patent Term
Restoration Act of 1984 (universally known as the Hatch-Waxman
Act).' This legislation authorized the Federal Food and Drug
Administration (FDA) to approve generic drugs 2 upon the
manufacturer's submission of proof of bioequivalence' Prior to
the Hatch-Waxman Act, in order to obtain FDA approval,
manufacturers of generic drugs were required to conduct the same
clinical tests as manufacturers of new, brand-name drugs.4 The
rigorous requirements for FDA approval narrowed the generic
1. Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended at 15
U.S.C. §§ 68b-68c, 70b (2006)).
2. Generic drugs are drugs made to the same chemical formula as an existing,
FDA-approved, brand-name compound.
3. The FDA defines bioequivalence as "pharmaceutical equivalents whose
rate and extent of absorption are not statistically different when administered to
patients or subjects at the same molar dose under similar experimental
conditions." Generally, this is determined by looking at pharmacokinetic
parameters such as the area under the curve, AUC(0 - Y), Cma, tmax, tl/2 and k1, of
the therapeutic moiety. See 21 CFR § 320.1 (2007).
4. A manufacturer of a new drug can file an application for FDA approval
after completion of required clinical trials, if the data support the safety and
effectiveness of the compound. These applications typically are 100,000 pages
or longer and include all the data gathered during development and in clinical
testing. The FDA is legally allowed six months for review of the application,
however, the average new drug application takes 30 months for review. See
generally 21 C.F.R. § 312 (2007).
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drug manufacturer's profit margin and stifled their growth,
inhibiting consumer access to affordable medicine. Thus, the
Hatch-Waxman Act marked the dawn of the generic drug era as
we know it.
After the passage of the Hatch-Waxman Act, the generic drug
industry grew tremendously in response to an increased demand
for lower-cost pharmaceuticals.' The Hatch-Waxman Act spurred
the generic drug industry's growth, in part, by an expedited
approval procedure for "small-molecule chemical compounds."6
However, what worked under the Hatch-Waxman Act for these
compounds is not a complete answer to the current problem of
high-cost medication. The FDA expedited approval procedure
under Hatch-Waxman excludes all recombinant protein or
"biologic" drugs.7
To remedy what the Senate perceives as a shortcoming in the
FDA expedited procedure, the Senate is currently considering the
Biologics Price Competition and Innovation Act of 2007
(Biologics Act). The Biologics Act is sponsored by Democrat
Senator Edward Kennedy of Massachusetts. Passage of this act
would essentially extend many of the provisions of the 1984
Hatch-Waxman Act to biologic drugs.8 This, in turn, would likely
promote development of lower-cost alternatives to increasingly
important biologic therapies. Furthermore, it could stimulate
growth in the generic drug industry comparable to that experienced
by small-molecule drug competitors after the passage of the Hatch-
Waxman Act.
Due to the differences between small-molecule and biologic
compounds, however, a number of problems arise when the Hatch-
Waxman provisions, which were originally developed for small-
molecule compounds, are applied to biologics. Specifically,
biologic compounds are larger and more complex than small-
5. In 2005, the generic drug industry represented 56% of all prescriptions
filled, and had annual sales of $16 billion. Barr Pharmaceuticals, Inc.,
www.barrlabs.com/generic/overview.php (last visited Apr. 28, 2008).
6. See infra notes 53-56 and accompanying text for a definition of "small
molecule chemical compounds" and a discussion of their properties.
7. See infra note 37 and accompanying text for a definition of "biologic"
drugs.
8. For an extended discussion of the similarities of the provisions in the
Biologics Act to those of the Hatch-Waxman Act, see infra Section II.
366
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molecule compounds. They are also synthesized by processes that
attempt to mimic in vitro biological production,9 in contrast to the
traditional combinatorial chemistry techniques used in laboratory
synthesis of small-molecule drugs."° Due to the differences in the
synthesis procedure, inconsequential changes in the manufacture
of small-molecule compounds could all have serious health
consequences if occurring in biologic production."
Aside from the health concerns associated with "generic
biologics,"' 2 there are a number of concerns about what the impact
of biologic legislation will be on United States patent law. First, if
it is impossible to synthesize an identical compound, the effect
could be to preclude patentability on the grounds of
"enablement."' 3 The patent-holders, here manufacturers of brand-
name drugs, should be prohibited from simultaneously arguing that
their patented compounds are impossible to replicate and that they
9. In vitro production, or synthesis within the living organism by its own
processes, is often mimicked in a laboratory setting using cloning techniques
and cell-line development.
10. Most small-molecule chemical compounds are not synthesized naturally
in vivo, unlike most biologics (for example, human growth hormone, a biologic,
is produced naturally in the anterior pituitary gland, while aspirin, a small-
molecule chemical compound, must be made outside the body). Development
and production of small-molecule compounds, then, are possible using
mainstream combinatorial chemistry techniques (e.g. high throughput screening,
cell-based assays, reaction-based chemistry), while biologic production requires
more sophisticated techniques.
11. See Richard Frank, Regulation of Follow-on Biologics, 357 NEw ENG. J.
MED. 841-43 (2007).
12. Instead of "generic biologics," these compounds are generally referred to
as "biosimilars" in Europe or "follow-on biologics" in the United States as an
acknowledgement of the impossibility of creating identical biologic compounds.
See Orrin G. Hatch, U.S. Senator, The Future of Biologics-Examining Market
Competition, Innovation, and Patient Safety, Address before the U.S. Chamber
of Commerce (April 25, 2007), available at
http://www.uschamber.com/webcasts/2007/070425 ncf biologics.htm
[hereinafter Hatch Address].
13. The enablement requirement of the first paragraph of 35 U.S.C. § 112
(2006) requires that the patent specification "enable" those skilled in the art to
make and use the full scope of the claimed invention without undue
experimentation based on the underlying facts. Genentech, Inc. v. Novo
Nordisk A/S, 935 F. Supp. 260 (Fed. Cir. 1997).
2008] 367
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are enabled.14  Second, patentability is at issue because many
biologics are compounds already produced in vivo, such as insulin
or human growth hormone. While the methods of synthesis for
this type of drug are complex and could potentially be novel, the
biologic itself might not meet the patentability requirement of
novelty. 5 These issues should be considered by legislators before
assuming that the provisions of the 1984 Hatch-Waxman Act will
prove as successful for biosimilars as they did for small-molecule
compounds in the 1980s.
This is not to say that the Hatch-Waxman Act is entirely without
merit when applied to biologics. While the concepts of the Hatch-
Waxman Act need complements in the biologic drug industry, the
nature of the differences between the drugs developed in the 1980s
and the drugs being developed today merit a closer look before we
can assume that the Biologics Act will procedure results similar to
the Hatch-Waxman Act.
Section II of this article provides a background of the issues
facing generic pharmaceuticals with the emergence of biologic
therapies. This section surveys the past attempts to regulate the
biologic industry. It also provides an overview of the special
circumstances facing biologics. Section III analyzes the legislation
proposed to ameliorate the problems in the approval process of
biologics. Finally, Section IV examines the likely effects of the
Biologics Act on the interested parties. This section also examines
how the Biologics Act relates to existing tenets of our patent law.
II. BACKGROUND
Any discussion of how to fix generic pharmaceutical approval
must begin with a discussion of the flaws in our current system. To
that end, Part A of this section provides an overview of the
ubiquity of generic drug use and the incumbent financial issues
14. See infra Section IV.
15. The requirement that an invention be novel in order to qualify for a
patent is found in 35 U.S.C. § 102 (2006). Other patentability requirements
include that the invention be useful, 35 U.S.C. § 101, that it be nonobvious, 35
U.S.C. § 103, and that it be enabled, have an adequate written description in the
specification, and disclose the best "mode" of making or using the invention, 35
U.S.C. § 112.
368
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surrounding it. Part B discusses the Hatch-Waxman Act, the
solutions it provided, and the effect of those solutions on the
pharmaceutical industry. Part C introduces biologic drugs and
discusses why they have been excluded from the current system of
FDA approval.
A. A Generic Problem
To the average consumer looking at the shelf in the drugstore,
the differences between Advil and Walgreen's ibuprofen tablets
are probably not apparent or significant. Noticeable differences
may be limited to the price tag and the trademarks. Consumers
have increasingly become accustomed to having a choice between
either a generic or a brand-name drug over the past three decades.
Generic alternatives are now a familiar and expected option in
drugstores, pharmacies, doctor's offices, and hospitals now that
generic pharmaceutical companies have sprung up to meet the
overwhelming need for lower-cost medication.
This need for lower-cost alternatives to brand-name drugs has
only grown in the nearly 25 years since Congress last considered
generic drugs. Indeed, skyrocketing pharmaceutical costs and
increased consumer demand have focused increasing attention on
generic drugs as a possible solution to the rising costs of
healthcare. As Senator Orrin Hatch of Utah recently noted while
discussing the future of generics:
A February report by the Center for Medicare and
Medicaid Services paints the picture very well:
America's health care spending in the next ten
years will double to $4.1 trillion. Or, to look at it
another way, that's 20 cents out of every dollar
spent. We spend about $7,500 per capita 6 on health
care in the U.S. Yet, in 2016, that will rise to an
astounding $12,800 per person. Greater spending
for pharmaceuticals is expected to fuel much of the
16. Per capita refers to the amount spent per unit of the population: by or for
each person.
2008]
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increase. 7
With such large a percentage of national spending tied to
healthcare, 47 million uninsured Americans in 2006 and another
38.3 million covered by Medicaid alone,' 8 the price of medication
is a critical issue for citizens and legislators alike. Prices are not
an isolated issue. Prices are inexorably linked to healthcare,
monetary and fiscal policy, management of the national debt, and,
ultimately, overall standard of living.
Drug prices are also an especially "hot-button" issue because of
the looming healthcare crisis in America. As the Congressional
Budget Office has stated:
Growth in health care spending has outstripped
economic growth regardless of the source of its
funding .... The major factor associated with that
growth has been the development and increasing
use of new medical technology .... In the health
care field, unlike in many sectors of the economy,
technological advances have generally raised costs
rather than lowered them. 9
This increase in inefficient spending, coupled with the
unraveling of employer-based healthcare plans and the rise of
Medicaid, contributes to a growing sense of panic about the future
of American healthcare.2" With the aging of the large "Baby
Boomer" generation and the incumbent increase in the cost of their
healthcare and medication, the public has finally realized that there
is a problem.2' Candidates for the 2008 presidential election have
capitalized on this fear. Nearly every debate included questions
17. Hatch Address, supra note 12.
18. Medicaid is a state-sponsored, need-based program to subsidize
healthcare costs for lower-income individuals. U.S. Census Bureau, Press
Releases, www.census.gov/Press-Release/www/releases/archives/
incomewealth/010583.html (last visited Apr. 28, 2008).
19. Paul Krugman & Robin Wells, The Healthcare Crisis and What to Do
About It, N.Y. REV. BOOKS, March 23, 2006, available at
http://www.nybooks.com/articles/18802 (alteration in original).
20. Id.
21. Id.
370
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about plans for stemming the tide of runaway healthcare costs.
For politicians, it is largely a self-preservation mechanism - the
staggering rate of growth of the percentage of the gross domestic
product (GDP) taken up by entitlement programs, such as
Medicaid, contributes heavily to the national debt and decreases
funds for federal spending.22 The rapid and seemingly unstoppable
rise in healthcare spending has created a looming crisis for
citizens, drug companies, healthcare providers, and politicians.
Generic alternatives have made an immense impression on the
pharmaceutical industry. In 1994, (ten years after the Hatch-
Waxman Act was passed), consumers of generic drugs saved
between $8 and $10 billion in retail pharmacies alone on
prescription drugs by purchasing generic drugs instead of brand-
name drugs.23
Though the financial impact on consumers has been significant,
the impact on research and development in the pharmaceutical
sector has been equally momentous. A report by the
Congressional Budget Office stated, "[b]etween 1983 and 1995,
investment in [research and development] as a percentage of
pharmaceutical sales by brand-name drug companies increased
from 14.7 percent to 19.4 percent. Over the same period, U.S.
pharmaceutical sales by those companies rose from $17 billion to
$57 billion. '2 4  Clearly, the introduction of generics into the
marketplace has not stifled research and development efforts by
companies marketing primarily brand-name drugs.
B. Take 1: The Hatch- Waxman Act of 1984
The Hatch-Waxman Act of 198425 was enacted to balance the
competing interests of parties affected by the introduction of
generic drugs onto the consumer market. In order to compete with
22. Id.
23. CONGRESSIONAL BUDGET OFFICE, How INCREASED COMPETITION FROM
GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE
PHARMACEUTICAL INDUSTRY ix (1998), http://www.cbo.gov/ftpdocs/6xx/
doc655/pharm.pdf.
24. Id. at xv.
25. Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended at 15
U.S.C. §§ 68b-68c, 70b (2006)).
2008]
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the brand-name drug manufacturers, the new generic
pharmaceutical companies needed a relaxed approval process and
an avenue for expedited patent litigation. Conversely, existing
brand-name pharmaceutical companies needed to maintain their
profit margins as an incentive to continue research and
development. Finally, the public needed access to safe and
affordable medication and a progressive drug market.
As a compromise to these competing interests, the Hatch-
Waxman Act specifically authorizes "Abbreviated New Drug
Applications" (ANDAs), which had been under discussion within
the FDA as a solution to their rigorous approval requirements.
2 6
ANDAs essentially allow a company that wants to produce a
generic version of a patented drug to bypass the FDA's
requirements of proving that the drug is safe and effective. So
long as the formula is identical to the brand-name drug, an ANDA
applicant is only required to submit proof of the bioequivalence of
the brand drug with the generic.27 After certain periods of market
exclusivity given to the original New Drug Application (NDA)
holder,28 a generic company may file an ANDA, which certifies
one of four things: (1) Paragraph I certifies that the drug has not
been patented; (2) Paragraph II certifies that the patent has
expired; (3) Paragraph III certifies the date on which the patent
will expire and that the generic will not go on the market until after
that date; or (4) Paragraph IV certifies that the patent is not
infringed or is invalid.29
26. See 21 U.S.C. § 3550) (2006); see also supra note 4 for a discussion of
FDA approval.
27. Gerald J. Mossinghoff, Overview of the Hatch-Waxman Act and Its
Impact on the Drug Development Process, 54 FOOD & DRUG L.J. 187, 189
(1999).
28. The manufacturer who requests FDA approval for a brand drug files a
New Drug Application and is awarded any "exclusivities" that apply to its
application. There are six major exclusivities under current U.S. regulations:
new chemical exclusivity, new use or indication exclusivity, new formulation
exclusivity, orphan drug exclusivity, pediatric exclusivity, and generic filer
exclusivity. These carry different periods of monopoly depending on which are
awarded. For a complete discussion, see MARTIN A. VOET, THE GENERIC
CHALLENGE: UNDERSTANDING PATENTS, FDA & PHARMACEUTICAL LIFE-
CYCLE MANAGEMENT, 57-65 (2005).
29. Mossinghoff, supra note 27, at 189.
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A party filing an ANDA under Paragraph IV must give notice to
the patent holder that it has filed an ANDA. The filing is
considered an act of literal patent infringement" for enforcement
purposes." The patent-holder then has forty-five days to file suit
for infringement. During this forty-five day period, the ANDA's
approval is suspended.3 2 If the patent holder chooses to file suit,
the ANDA will not be processed for another thirty months. This
allows both parties to litigate the Paragraph IV allegation.33 The
notice requirement and thirty-month stay of approval, coupled with
patent term extensions and market exclusivity provisions awarded
in some circumstances,34 make the Hatch-Waxman Act attractive
for brand-name drug manufacturers. However, if the generic
company prevails and can show noninfringement or invalidity of
the patent under Paragraph IV, it is awarded 180 days of market
exclusivity for the generic version of the drug. This provision
makes ANDAs attractive to generic companies as well.35
Before reaching its current form, several provisions of the
Hatch-Waxman Act had been modified by the Medicare Act of
2003.36 The two most notable alterations included: (1) requiring
brand-name manufacturers to sue within forty-five days or else
forego later suit, thus precluding manufacturers from waiting for
damages to accrue because generic manufacturers had begun
marketing; and (2) codifying Mova Pharmaceuticals,37 which held
that a district court decision does not trigger the 180-day
exclusivity for the generic manufacturer until an appeal has been
30. As opposed to infringement under the doctrine of equivalents, which
"allows a finding of patent infringement even when the accused product does
not fall within the literal terms of the claims." TrafFix Devices, Inc. v. Mktg.
Displays, Inc., 532 U.S. 23, 31 (2001).
31. 35 U.S.C. § 271(e)(2) (2006); see also Eli Lilly & Co. v. Medtronic, Inc.,
496 U.S. 661, 678 (1990).
32. Bristol-Myers Squibb Co. v. Royce Labs., 69 F.3d 1130, 1132 (Fed. Cir.
1995).
33. See 21 C.F.R. § 314 (2007).
34. See CONGRESSIONAL BUDGET OFFICE, supra note 23, at xiv.
35. Id.
36. The Medicare Prescription Drug, Improvement, and Modernization Act
of 2003, Pub. L. 108-173, 117 Stat. 2066 (codified as amended in scattered
sections of 42 U.S.C.).
37. Mova Pharm. Corp. v. Shalala, 955 F. Supp. 128 (D.D.C. 1997); see also
21 C.F.R. § 314.107(e) (2007).
2008]
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denied or waived.38 Prior to passage of the Medicare Act of 2003,
a prevailing generic manufacturer would have to choose between
risking the loss of the exclusivity allowed under Hatch-Waxman
and risking the possibility that the noninfringement or invalidity
ruling would be overturned on appeal. The latter possibility could
result in treble damages against the manufacturer, for its
intervening acts of infringement.39
The procedure for generic drug approval mapped out in the
Hatch-Waxman Act has since become the standard method of
operation for generic drug manufacturers. It has also succeeded in
furthering the public's interest in timely access to lower-cost
generic drugs after the expiration of the brand-name drugs'
patents." The six-month exclusivity awarded to the first
successful Paragraph IV filer, however, has delayed the low cost
access to generic drugs. The period of exclusivity allows generic
marketers to charge initial prices almost as high as the brand-name
drugs and creates tremendous profit potential." By narrowing the
field to only two competitors, namely the brand-name drug
manufacturer and one generic manufacturer, the generic
manufacturer can easily keep its price just below that of the brand-
name drug manufacturer, who is trying to recoup the high research
and development costs associated with pharmaceutical
development.42 Though generic manufacturers incur litigation
costs, cost of a legal advisory opinion,43 additional development
38. Amphastar Pharm., Pre-Effective Amendment to Registration Statement
(Form S-i/A), at 53-54 (May 13, 2005).
39. Mova Pharm. Corp. v. Shalala, 140 F.3d 1060, 1065 (D.C. Cir. 1998).
40. See supra note 5 and accompanying text.
41. A. Maureen Rouhi, Beyond Hatch- Waxman, CHEMICAL & ENGINEERING
NEWS, Sept. 23, 2002, at 53-54.
42. Estimates of the cost of developing a new molecular entity (novel drug)
run the gamut from $800 million to $2 billion per drug. Economists estimate
that only thirty percent of the compounds developed will actually make money
for the developer. However, continued investor confidence in the industry
enables large-scale research and development to continue apace. Neal Masia,
The Cost of Developing a New Drug, in Focus ON INTELLECTUAL PROPERTY
RIGHTS (2006), http://usinfo.state.gov/products/pubs/intelprp/cost.htm.
43. Generally before filing a Paragraph IV ANDA, a generic manufacturer
will request an advisory opinion from outside counsel regarding infringement
and validity of any patents covering the compound, method of manufacture or
synthesis, or use.
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costs, and filing costs associated with an ANDA, they have few
expenses compared to brand-name manufacturers.
Barr Pharmaceuticals," for example, recently filed a Paragraph
IV ANDA covering Prozac and successfully invalidated Eli Lilly's
patents covering the compound. In the six-month period of
exclusivity alone, sales of the generic drug reached $3 11 million.4 5
This kind of profit is a powerful incentive for litigation under the
Hatch-Waxman Act, and the incentive has worked. The litigation
costs are not a powerful enough deterrent to make generic
pharmaceutical companies think twice about using the
reexamination procedures. As a result, a flood of ANDA litigation
has ensued.46
C. Biologics-the "Black Sheep" of the Hatch- Waxman Family
Despite challenges to the Hatch-Waxman Act, it has expedited
approval of generic drugs, significantly lowering costs for the
consumer. The Act, however, applies only to medications
classified as small-molecule chemical compounds.47 The Hatch-
Waxman Act does not cover recombinant protein drugs, also
44. Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company
operating in more than thirty countries worldwide. Along with their
subsidiaries, Barr Laboratories, Duramed Pharmaceuticals, and PLIVA, they
develop, market, and manufacture generic and proprietary drugs,
biopharmaceuticals, and active pharmaceutical ingredients. They currently
market more than 120 generic and 25 proprietary drugs in the U.S., and more
than 550 products worldwide. Barr Pharmaceuticals, Inc.,
http://www.barrlabs.com (last visited Apr. 28, 2008).
45. Masia, supra note 42.
46. See The Generic Drug Maze: Speeding Access to Affordable, Life Saving
Drugs: Hearing Before the S. Spec. Comm. On Aging, 109th Cong. (2006)
(statement of Gary Buehler, Director, Office of Generic Drugs, Food and Drug
Administration). In 2000, the FDA received 335 ANDAs and approved 294 of
them. Five years later, in 2005, the number of submissions had grown to 766,
with only 467 approvals. Id.
47. In 1984, at the time the Hatch-Waxman Act was passed, only one
biopharmaceutical drug had been approved for use. Recombinant human insulin
was marketed by Eli Lilly starting in 1982 under the brand name Humulin. The
biotechnological processes required to synthesize biologics were still being
developed at that time, and so legislators naturally focused their efforts towards
small-molecule treatments only for the Hatch-Waxman Act.
2008] 375
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known as biologics. Biologics are an increasingly important group
of therapeutic compounds, but they have no avenue for approval of
generic alternatives in the United States.
Biologics are drugs that are created using biotechnological
processes that simulate biological molecules (e.g. insulin, human
growth hormone, interferon, erythropoietin, vaccines). Biologics
are, generally, significantly larger and more complex molecules
than traditional pharmaceuticals.48 For example, they cannot
easily survive the acidic conditions of the stomach or pass through
the lining of the intestine and into the bloodstream. As a result,
they are usually injected directly into the bloodstream.49 Also, due
to the size of these compounds, the immune system occasionally
attacks biologics present in the bloodstream, leading to undesirable
side effects.5" For example, when Johnson & Johnson changed
their manufacturing process for a new anemia drug, the new
formulation unexpectedly caused certain compounds to leach out
of the uncoated rubber stoppers used in drug storage. This caused
clumps to form in the bloodstream and triggered an extreme form
of anemia - the very disease that the drug was designed to treat.5
Antibody-induced pure red cell aplasia was also a concern in
European testing guidelines for erythropoietin biosimilars 2
Biologic compounds differ from small-molecule compounds in
three significant ways. First, their physical characteristics are
markedly different. Small-molecule drugs may be composed of
dozens of atoms, and their size or molecular weight may be
measured in hundreds of daltons 3 They can be described by a
48. See Center for Biologics Evaluation and Research, Frequently Asked
Questions, http://www.fda.gov/cber/faq.htm#4 (last visited Apr. 28, 2008).
49. In contrast, small-molecule compounds are usually delivered via oral
dosage.
50. H. Schellekens, Biosimilar Therapeutic Agents: Issues with
Bioequivalence and Immunogenicity, 34 EUR. J. CLINICAL INVESTIGATION 797,
797-99 (2004).
51. Xenia P. Kobylarz, The Patent Killer, IP LAW & Bus., May 2007, at 28.
52. Andrzej Wiecek & Ashraf Mikhail, European Regulatory Guidelines for
Biosimilars, 21 NEPHROLOGY DIALYSIS TRANSPLANTATION v17, v19 (Supp. 5
2006); see also Michele Kessler et al., Immunogenicity of Biopharmaceuticals,
21 NEPHROLOGY DIALYSIS TRANSPLANTATION v9, vl0 (Supp. 5 2006).
53. A "dalton" is the standard name given to an atomic mass unit in
biochemistry or molecular biology literature. One dalton equals I/NA grams,
376
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fixed chemical formula, and, thus, can be chemically synthesized
in a lab. Their mechanism of action is usually understood, since
they are ordinarily developed with a specific target and function in
mind. Biologics, by contrast, are often composed of millions of
atoms which can weigh hundreds of kilodaltons. They typically
cannot be described by a single chemical formula. As a result,
they must be synthesized by organisms such as bacteria or a cell
culture. Their mechanism of action is usually imperfectly
understood. "
Second, the process of manufacture differs tremendously
between small-molecule compounds and biologics. The starting
materials for small-molecule drug synthesis are chemicals.
Biologics, in contrast, are usually begun with either a DNA
plasmid vector55 and cells, which mimics in vitro production, or a
whole animal. The vessel for the synthesis of small-molecule
drugs is a specialized glass or metal container; for biologics it is a
cell line or a whole animal. Synthesis of biologics can require
hundreds of specific isolation and purification steps. 6 An exact
copy is therefore impossible, since changes to the compound itself
occur unexpectedly during the process. As professors Roger and
Mikhail observe, "side chains can be added, the product can have
alterations to its tertiary or quarternary structure through protein
misfolding; degradation by oxidation or deamidation can also
occur." 57  These problems are not exclusive to laboratory
simulation of the body's production of the compound. The same
where NA is equal to Avogadro's number.
54. The Law of Biologic Medicine: Hearing Before the S. Comm. on the
Judiciary, 108th Cong. (2004) (statement of Dr. William Hancock, Chair of
Bioananalytical Chemistry, Northeastern University) [hereinafter Hancock
Testimony].
55. Plasmid vectors are small, circular molecules of double-stranded DNA. A
piece of DNA can be inserted through use of a restriction endonuclease and
introduced into a host cell that will express the inserted DNA in the form of a
desired trait.
56. Hancock Testimony, supra note 54; see also Simon Roger & Ashraf
Mikhail, Biosimilars: Opportunity or Cause for Concern?, 10 J. PHARMACY &
PHARMACOLOGICAL SCI., 405 (2007) available at
http://www.ualberta.ca/-csps/JPPS 10_3/ReviewArticle_ 1308/MS 1308_Format_
final.pdf.
57. Roger & Mikhail, supra note 56, at 406.
2008]
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problems occur frequently in vivo as well. Human cells, however,
have developed a proofreading mechanism that reviews each
synthesized protein and can usually remove the "mistakes" before
serious problems occur."
Third, manufacturing biologics can pose several problems,
including: (1) the nature of manufacture; (2) the unlikelihood that
a generic manufacturer could successfully reverse engineer the
exact steps of synthesis used by the brand manufacturer; (3) the
complexity and size of the molecules; (4) the possibility for
serious and unpredictable side effects with even a small change;
and (5) the difficulty of quality control, for even a meticulous
replication of a biological compound is not identical to the
developed compound it attempts to mimic. 9 Such drugs are thus
termed "biosimilar," since similarity to the biological molecule is
all that can realistically be claimed.6" Senator Hatch reiterated the
distinction in his remarks to the U.S. Chamber of Commerce,
when he said, "[t]he concept of bioequivalence simply cannot be
introduced into this debate .... Instead, we must work carefully
to define biosimilarity."61
III. PROPOSED LEGISLATION: THE BIOLOGICS PRICE COMPETITION
AND INNOVATION ACT OF 2007
A. Finding a place for Biotechnology - the Need for Legislative
Reform
At the Biosimilars 2007 Conference on September 24, 2007,
Representative Henry Waxman remarked:
Biotech drugs are the future of medicine. There are
58. Id.
59. See Hancock Testimony, supra note 54.
60. Without the same cell line, (and sometimes even with the same cell line)
the nature of biological processes dictates that the products will not be identical.
Until stem cell technology provides a workable alternative to the current
manufacturing processes (cloning and recombinant DNA technology),
similarity, not equivalence, is all that can be claimed. See id.
61. Hatch Address, supra note 12.
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close to 500 biotech drugs currently in development
for a host of serious diseases. In 2006, U.S. biotech
sales grew by 20% to $40.3 billion. By way of
comparison, this 20% growth in biotech sales is far
greater than the 8% sales growth experienced by
traditional pharmaceuticals.62
With therapeutic biotechnology becoming an ever-growing
field, the market demands a lower-cost alternative to biologic
therapies.63  Unfortunately, there is no approval process for
production of these alternatives under existing U.S. law. Congress
has realized as much, and it is currently addressing this problem
through the Biologics Act of 2007. 4 As the Biologics Act stands
in the Senate, it will amend the Public Health Service Act 65 to
allow applications for licensure of biological products based on
their similarity to already-licensed products.
Currently, most new biologics are not regulated as new drugs
under the Food, Drug, and Cosmetic Act. Instead, they are
regulated under the Public Health Service Act. Therefore, instead
of filing a new drug application (NDA), an applicant must file a
biologics application (BLA). A BLA certifies that the product is
safe and pure, and that the manufacturing facility is designed to
ensure those characteristics.66 An applicant, however, may not
currently file a BLA for a biosimilar.
To complicate matters, some of the smaller, less complex
biologics (such as insulin and human growth hormone) have
received initial approval for manufacture via an NDA. As such,
these biologics are eligible for generic approval through an
ANDA. There is, however, no clear line between those biologics
that qualify for an NDA and those that do not. No bright-line size,
weight, or complexity standards exist to guide manufacturers in
62. Congressman Henry A. Waxman, Remarks at Biosimilars 2007
Conference (Sept. 24, 2007), available at
http://www.biosimilarstoday.com/Waxman.pdf [hereinafter Waxman Remarks].
63. Id. at 2.
64. Biologics Price Competition and Innovation Act of 2007, S. 1695, 110th
Cong. (2007).
65. Public Health Service Act, ch. 373, 58 Stat. 682 (codified as amended at
42 U.S.C. §§ 201-300 (2006)).
66. See 42 U.S.C. § 262 (2006).
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the decision of whether to file an NDA or a BLA application.
William Schultz, speaking for the Generic Pharmaceutical
Association, noted:
It is true that today the FDA regulates most
biopharmaceuticals under the Public Health Service
Act, which, as previously discussed, is not part of
the Hatch-Waxman regime. But the Public Health
Service Act has for many years contained a
provision stating that nothing in that Act shall affect
the FDA's jurisdiction under the FDCA, and it is
clear that FDA could regulate all
biopharmaceuticals under the FDCA, as it had
chosen to do for insulin and human growth
hormone. 67
That said, the FDA has been reticent to do so.
The Biologics Act was impelled not only by the need to clarify
some of these issues but also in response to the district court
decision in Sandoz, Inc. v. Leavitt.6" In Sandoz, Inc., the district
court for the District of Columbia directed the FDA to refrain from
further delay in deciding whether to approve the license of
Omnitrope.6 9 Omnitrope, a human growth hormone biologic, was
a candidate for approval via a BLA, but the court attempted to put
pressure on the FDA to deal with the growing confusion by
ordering the agency to respond to the NDA. The agency granted
the approval but appealed the decision to the Federal Circuit. It
also asserted that it was approving Omnitrope as a "follow-on
protein product," not as a biologic."0 The FDA emphasized that
this did not provide a guaranteed pathway for approval of other
67. The Law of Biologic Medicine, Hearing Before the S. Judiciary Comm.,
108th Cong. (2004) (statement of William B. Schultz, Partner, Zuckerman
Spaeder, on behalf of the Generic Pharmaceutical Association). [hereinafter
Schultz Testimony].
68. Sandoz, Inc. v. Leavitt, 427 F. Supp. 2d 29 (D.D.C. 2006).
69. Id. at41.
70. See Omnitrope Questions and Answers,
http://www.fda.gov/cder/drug/infopage/somatropin/qa.htm (last visited Apr. 28,
2008).
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biosimilars."
A prompt legislative response is crucial to clarify the FDA's role
and responsibilities in the approval process and prevent continued
monopolies, as patents covering the first generation of biologic
therapies are beginning to expire. An estimated $28 billion worth
of biologic drugs are expected to come off patent by 2015.72 With
no pathway for generic approval, the effect will be to grant a
perpetual monopoly for the brand-name biologic manufacturer.
Such a result would undermine the purpose of U.S. patent law,
which is to grant manufacturers only limited monopolies.
The Biologics Act is accompanied in the House of
Representatives by the Access to Lifesaving Medicine Act of 2007
(H.R. 1038), which is sponsored by Democrat Representative
Henry Waxman of California. It has since been referred to the
House Subcommittee on Health and the House Judiciary
Committee.73
The Senate bill of the Biologics Act was introduced on June 26,
2007. Since then it has been cleared by the Committee on Health,
Education, Labor, and Pensions (HELP) and slated for a vote in
the Senate.74 The Biologics Act requires FDA approval of a
biosimilar if the applicant can demonstrate the interchangeability
of the compound with its brand-name counterpart.
Interchangeability can be shown if: (1) the biosimilar "can be
expected to produce the same clinical result as the reference
product in any given patient"; and (2) the risk in terms of safety or
diminished efficacy of alternating between the products is not
greater than the risk of using the original (or "reference product")
without switching.75
71. Id.
72. ENGEL & NOVITT, LLP, POTENTIAL SAVINGS THAT MIGHT BE REALIZED
BY THE MEDICARE PROGRAM FROM ENACTMENT OF LEGISLATION SUCH AS THE
ACCESS TO LIFE-SAVINGS MEDICINE ACT (H.R. 6257/S. 4016) THAT
ESTABLISHES A NEW CBLA PATHWAY FOR FOLLOW-ON BIOLOGICS 12 (2007),
http://www.pcmanet.org/issues/index.php?section=2 (follow "Engel & Novitt
Follow-on Biologics Paper" hyperlink).
73. THOMAS (Library of Congress), http://thomas.loc.gov/cgi-
bin/bdquery/z?dl 10:HR01038:@@@C (last visited Apr. 28, 2008).
74. THOMAS (Library of Congress), http://thomas.loc.gov/cgi-
binlbdquery/z?dl 10:SN01695:@@@X (last visited Apr. 28, 2008).
75. S. 1695, 110th Cong. § 2(a)(2) (2007) (proposed amendment of 42
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Despite the route an applicant has chosen to prove
interchangeability, the applicant must submit the following with
his application:
(1) analytical studies that demonstrate that the
biological product is highly similar to the reference
product notwithstanding minor differences in
clinically inactive components;
(2) animal studies; and
(3) a clinical study or studies (including the
assessment of immunogenicity and
pharmacokinetics or pharmacodynamics) that are
sufficient to demonstrate safety, purity, and potency
... and designed to avoid needlessly duplicative or
unethical clinical testing. 76
The FDA may waive one or more of these requirements if the
applicant presents other supplementary information or if the
biologic is comparatively simple. Any finding of
interchangeability, however, is prohibited until at least one year
after the reference compound is commercially marketed.
In order to be "highly similar" under the first element of
interchangeability, the biosimilar must be identical to the brand-
name biologic in terms of the route of administration of the
biosimilar, the dosage form and strength, the mechanism of action,
and the condition for which the product is developed. 77
In addition to the simplified requirements for approval outlined
above, another difference between the Hatch-Waxman Act of 1984
and the Biologics Act is the length of market exclusivity granted to
a new, brand-name (or "innovative") compound. Previously, NDA
filers would have to qualify for an exclusivity classification (e.g.
Pediatric Exclusivity, New Molecular Entity, Orphan Drug
Exclusivity) to gain such market exclusivity.78 The Biologics Act
provides for an automatic twelve-year exclusivity from the date of
approval for any innovative application, in contrast to the five-year
exclusivity for new molecular entities under Hatch-Waxman. This
U.S.C. § 262(k)(4) (2006)).
76. Id. (proposed amendment of 42 U.S.C. § 262(k)(2)(A)(i)(I) (2006)).
77. Id. (proposed amendment of 42 U.S.C. § 262(k)(2)(A)(i)(II)-(IV)
(2006)).
78. See Krugman & Wells, supra note 19.
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longer exclusivity is intended, in part, to offset the higher
difficulty level required to perfect the product during research and
development.
The HELP committee approved the bill largely as drafted,
although language was added to clarify the sponsors' intent that
innovating products should receive only a single twelve-year
exclusivity period from the time of initial approval.8" In reference
to the change, Senator Kennedy stated, "We added a provision...
specifying that this phrase 'first-licensed' does not apply to any
supplemental application or even a new license for a new
indication, route of administration, dosage form or strength."'"
Senator Kennedy's clarification was in response to the generic
community's concern that a minor and superficial change to the
licensed product could entitle the brand-name manufacturer to an
additional twelve-year exclusivity - a practice known as
"evergreening."
Many of the other provisions of Hatch-Waxman seem to have
simply carried forward into the text of the Biologics Act, though
some provisions have slightly different timescales. After filing a
biosimilar application, for example, the applicant has 20 days to
notify the patent holder.2 Within 60 days of receipt of this notice,
the patent holder must issue a list of patents it believes the
biosimilar will infringe. The applicant then has 60 days to submit
an opinion of invalidity, unenforceability, or noninfringement.
After that, the patent holder has 60 days to respond. 3 Litigation
then takes place if necessary, as under the Hatch-Waxman Act.
Though several prior bills have tangentially addressed the need
to extend generic approval to biologic drugs, this is the first to
garner significant bipartisan support.8 4 This is demonstrated by the
79. See Hancock Testimony, supra note 54.
80. M. Nielsen Hobbs, Follow-On Biologics Bill Clears Senate Committee
With Stronger Language on Exclusivity Cap, FDALEGISLATIVEWATCH, June
27, 2007, http://www.fdalegislativewatch.com/2007/06/follow-on-biolo.html.
81. Id. (alteration in original).
82. S. 1695, 1 10th Cong. § 2(a)(2) (2007) (proposed amendment of 42
U.S.C. § 262(l)(2)(A) (2006)).
83. Id. (proposed amendment of 42 U.S.C. § 262(l)(3) (2006)).
84. See, e.g., Access to Life-Saving Medicine Act, H.R. 1038 & S. 623,
110th Cong. (2007); Affordable Biologics for Consumers Act, S. 1505, 11 0th
Cong. (2007); Patient Protection and Innovative Biologic Medicines Act of
2008]
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three democrats and two republicans who sponsor it. The
Biologics Act is also the first bill addressing biosimilars that
Senator Orrin Hatch, an architect of the Hatch-Waxman Act, has
supported. Senator Hatch stated that he was waiting for a bill that
recognized the interests of both generic and novel drug
manufacturers.
Despite Hatch's optimism that the proposed legislation achieves
such a balance, not all members of Congress are as sanguine.
Senator Sherrod Brown of Ohio drafted an amendment to the bill
that would shorten the automatic exclusivity period from twelve to
seven years.85 Senator Brown is likely seeking the support of
generic manufacturers who are disinclined to support a proposal
that would shorten their opportunity for profit so drastically. A
twelve-year exclusivity, however, might decrease the amount of
litigation, because it could prove to more profitable to simply wait
the additional eight years until the patent expires rather than to
engage in costly litigation beforehand. Ultimately, though,
Senators Enzi, Clinton, Hatch, and Kennedy were unwilling to
reconsider their position, and Brown withdrew the amendment
without a vote.
Representative Henry Waxman also had concerns about the
length of the exclusivity. He stated:
In the current debate, the industry is calling for 10
or even 14 years of exclusivity. Those periods are
so long that they are not only unbalanced, they
make the bill a huge give away. Brand companies
should receive a reasonable term of exclusivity, but
not one that is so long that it would rob the
American people of the cost-savings appropriate
generic competition brings.
If the Congress ignores the lessons we learned
about balance in Hatch-Waxman and passes a bill
that puts too much weight on one side of the scale -
and replaces adequate incentives with windfall
profits - we will lose a huge opportunity.
86
2007, H.R. 1956, 110th Cong. (2007).
85. See Hobbs, supra note 80.
86. Waxman Remarks, supra note 62, at 6-7.
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Alternatively, two other amendments were also considered.
Both amendments would have extended the blanket twelve-year
exclusivity by six months. Senator Lamar Alexander of Tennessee
proposed the addition of a pediatric exclusivity. Senator Richard
Burr of North Carolina proposed an additional six months be given
for new indications or uses. Both amendments were ultimately
defeated.87
The twelve-year exclusivity has been the white flag in the tug-
of-war contest between generic and brand drug manufacturers and
their constituent interest groups. The Generic Pharmaceutical
Association calls the twelve years "excessive," while the
Biotechnology Industry Organization (BIO)"8 insists that fourteen
years are necessary to ensure continued innovation. 9  Teva
Pharmaceuticals, a large manufacturer of many generic drugs,
added:
Unfortunately, there are . . . issues that undermine
the promise of the bill for consumers, payers and
employers who continue to face increasing health
care costs. The first issue is the unprecedented
twelve years of market exclusivity the bill provides
to the innovator company for developing a
compound. Teva, as a significant patent holder,
supports strong incentives for innovation, however,
twelve years of market exclusivity is four years
beyond any other nation and seven years beyond
the exclusivity period guaranteed for chemical
drugs. Our hope is that the Congress will adopt a
more constructive and balanced market exclusivity
87. See Hobbs, supra note 80.
88. BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across the
United States and 31 other nations. BIO members are involved in the research
and development of healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO International Convention,
the world's largest gathering of the biotechnology industry. See 310,
www.bio.org/aboutbio (last visited Apr. 28, 2008).
89. Press Release, BIO, Data Exclusivity Is Necessary to Support Future
Biotech Medical Breakthroughs (May 3, 2007), available at
http://www.bio.org/news/newsitem.asp?id=2007_0503_01.
20081 385
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period that is closer to the Hatch Waxman Act.9
The other proposed bills that have addressed this issue do
nothing but add confusion to the debate. For example, while H.R.
1030, the Biologics Act's House of Representatives' counterpart,
gives no exclusivity at all, H.R. 1956, the Access to Life-Saving
Medicine Act, provides for a fourteen-year innovator exclusivity.
Since the sponsors of the Biologics Act remain committed to the
twelve-year length, however, it seems unlikely that Congress will
either extend or shorten it by any significant amount.
Hoping to offset the generic manufacturers' displeasure with the
length of the exclusivity given to innovators, the sponsors also
included a one-year exclusivity for the first filer whose application
for biosimilar approval (the ANDA equivalent) is granted.9
Senator Kennedy commented that he hoped to attach the Bill to
the Prescription Drug User Fee Act reauthorization bill, which was
signed into law on September 27, 2007, by President Bush.
Unfortunately, the Bill was not ready in time. Nevertheless, the
sponsors remain confident in the balance achieved by the drafters.
Senator Hatch stated:
Biologics are the future of medicine, and this bill
ensures that we will continue to lead the world in
biotechnology . . . . We've achieved a good
balance. We give incentives to continue biological
development. We allow generic companies to do
what they do best - bring low-cost versions to the
market. And we ensure that patients and providers
not only have access to low-cost biologics but that
they're also safe. 92
90. Teva Comments on the Biologics and Price Competition Act of 2007,
Bus. WIRE, June 27, 2007, available at
http://www.allbusiness.com/services/business-services/4542977-1 .html.
91. S. 1695, 110th Cong. § 2(a)(2) (2007) (proposed amendment of 42
U.S.C. § 262(k)(6)(A) (2006)).
92. Press Release, Sen. Edward M. Kennedy, Lawmakers Praise Committee
Passage of Biologics Legislation (June 27, 2007) available at
http://kennedy.senate.gov/newsroom/press-release.cfin?id=f669f22b-dfae-
4341-827f-4624ceb8d291.
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Senator Clinton added:
This has real life, real world consequences. As soon
as we enact this bill, there are medications for
Hepatitis C, multiple sclerosis, cancer and diabetes
that will be available for generic versions that will
be more affordable for many more people than
currently is possible. With this committee's action
today, I am proud that we will both continue the
creativity and innovation that is absolutely essential
to our pharmaceutical industry and the lifesaving
treatments and interventions they are able to
provide for us and create a generic path that will
begin to lower prices and extend the availability of
so many of these treatments to more who need
them. "
Despite the hopes of the sponsoring Senators and their
confidence in the balance they have achieved, many still have
doubts. Representative Waxman, for example, called the chances
that any biologics legislation will pass through this congress
"extremely slim."94  Many legislators are reluctant to put their
name to a bill that might alienate either sector of the
pharmaceutical industry, particularly since the industry has been so
vocal about its opposition to the Bill.
B. Industry Responses
The debates surrounding the Bill are not limited to the
congressional chambers. Generic and brand pharmaceutical
manufacturers, along with special interest groups and consumer
advocates, are making their opinions known.
The Pharmaceutical Research and Manufacturers of America
said in a press release that they "remain concerned that patient
safety could be at significant risk if the current legislative follow-
on biologics proposals move forward."95 Generic manufacturers
93. Id.
94. Pharmalot, http://www.pharmalot.com/ (Sept. 7, 2007, 07:28 EST).
95. Press Release, Pharmaceutical Research and Manufacturers of America,
2008] 387
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responded with confidence in their ability to preserve
bioequivalence while ensuring safety. Barr Pharmaceuticals stated:
The science to create affordable generic biotech
drugs exists today.... It is being done every time a
brand manufacturer changes a manufacturing
process or location and uses comparability to ensure
the biotech drug will provide the same safety and
efficacy.
[B]iotech firms routinely justify process and site
changes via comparability studies. For example, if
an innovator biotech company seeks changes in
processes supporting the manufacture of their
products, or seeks to change the manufacturing
location of a product, comparability is the process
by which the amended product is judged to provide
the same clinical effect and safety profile.
96
Speaking for smaller innovative biotechnology companies, Dr.
Geoffrey Allan, CEO of Insmed, Inc., stated he believes that safe
biosimilars are possible. 97 He likened the process of ensuring
bioequivalence of biosimilars to the safety checks that are
necessary when any biologic manufacturer changes place of
manufacture, makes a change in the starting cell line, or changes
any step in the manufacturing process. 98 If an innovative biologic
manufacturer can move production from a plant in the U.K. to a
plant in Colorado, as Allan did for Insmed's IPLEX biologic, all
while ensuring that the product maintains the same properties, then
it should theoretically be possible to ensure that the properties
PhRMA Statement on Follow-On Biologics Legislation (Apr. 5, 2007),
available at
http://www.phrma.org/news-room/press-releases/phrma-statement on-follow-
on-biologics-legislation/.
96. Barr Pharmaceuticals, Inc., Generic Biologics-An Unmet Opportunity to
Save Billions on American Healthcare, available at
http://www.barrlabs.com/overview/government/BRL,-pp-biologics.pdf
97. Safe and Affordable Biotech Drugs-the Need for a Generic Pathway:
Hearing Before the H. Comm. on Oversight and Government Reform, 110th
Cong. (2007) (statement of Geoffrey Allan, Chief Executive Officer, Insmed,
Inc.).
98. Id.
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remain the same from innovative biologic to biosimilar.99
Some have noted that, ultimately, it may be immaterial whether
biosimilars gain an avenue for FDA approval, since it is still the
doctors and patients who must be convinced. As one commentator
noted, compared to payers and academics, doctors have always
been the toughest sell for generic drugs. "When choosing between
a branded pioneer biologic and a quasi-generic of uncertain
bioequivalence, doctors have been exceptionally reluctant to
switch." "
That said, there is some concern that the proposed legislation
does not protect the doctor's ability to prescribe the innovative
biologic in place of a potential biosimilar. This would make the
medical community's acceptance ultimately unimportant. BIO
stated that they were concerned that the proposed bill will allow
biosimilars to be substituted for the original product without the
intervention of the prescribing doctor, thus taking medical
decision-making out of the hands of a patient's doctor.' The
FDA agreed, stating, "patients should not be switched form [sic]
the innovator biological product to a follow-on biological product
(or vice versa) without the express consent and advice of the
patient's physician, and legislation should not allow for
determination of interchangeability at this time."'02
IV. ANALYSIS
Because the Biologics Act is a compromise between so many
interest groups, industry sectors, and individuals, there are still a
number of concerns in adopting the legislation. Part A of this
Section asks if the compromise reached will be economically
efficient, while Parts B and C will draw comparisons to
mechanisms for biosimilar approval in other world markets. Parts
99. Id.
100. John E. Calfee, Facing Reality on Follow-on Biologics, HEALTH POL'Y
OUTLOOK, April 24, 2007, at 3, available at
http://www.aei.org/publications/pubLD.260 1 0/pub-detail.asp.
101. Press Release, BIO, Leading Biotechnology Organizations Praise Effort
and Express Concern with New Follow-On Biologics Proposal (June 27, 2007),
available at http://bio.org/news/newsitem.asp?id=2007_0627_02.
102. Id.
2008] 389
25
Corbitt: The Pharmaceutical Frontier: Extending Generic Possibilities to B
Published by Via Sapientiae, 2016
DEPAULJ. ART, TECH. &IPLAW [Vol. XVIII:365
D and E then analyze the interplay of the legislation with the
patentability requirements of enablement and novelty,
respectively.
A. Will The Biologics Act Work Economically?
There are many advantages to using the same regulatory
framework in the pending legislation as is used under the Hatch-
Waxman Act. The most notable of these is the quarter-century of
experience, observation, and troubleshooting that parties have
already had with the latter. By using provisions similar to those of
the Hatch-Waxman Act, legislators have an idea of how courts will
interpret the Act. It also allows use of market data that can give an
estimate of effects of the law on various parties. Predictability is
invaluable to lawmakers as they attempt to broker the necessary
compromises between the disparate interests. Enacting Hatch-
Waxman-like provisions also provides the courts with persuasive
precedent they can use to interpret the new biosimilars law.
Finally, it also provides guidance to the FDA, which will be the
entity enforcing the Bill.
The Biologics Act was introduced as the next step in the
evolution of the Hatch-Waxman Act, but it is uncertain whether
biosimilars are really conducive to a Hatch-Waxman-like process
of approval and generic manufacture. The requirements of the
Biologics Act, notably the extensive clinical studies required for
the application" 3 (unlike an ANDA, which merely requires a
showing of bioequivalence-i.e. that the generic compound
performs in the same manner as the innovative drug"0 4), will
undoubtedly increase biosimilar manufacturer's costs and decrease
the margin between the price of the original and the price of the
biosimilar. Initial estimates are that biosimilars will be priced
between 10% and 20% lower than the brand-name counterparts,'0 5
103. S. 1695, 110th Cong. § 2(a)(2) (2007) (proposed amendment of 42
U.S.C. § 262(k)(2)(A)(i)(I) (2006)).
104. Abbreviated New Drug Application,
http://www.fda.gov/cder/regulatory/applications/ANDA.htm. (last visited Apr.
28, 2008).
105. JEANETTE MARCHANT, THE FUTURE OF BIOsIMILARS (2007) available
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compared to an average 71% savings on small-molecule generic
drugs."6 The development costs of biosimilars are also much
higher than the $1 million to $2 million expected development
costs of a small-molecule generic. The expected cost of
development ranges from $10 million to $40 million.' 7 When
coupled with the possibility that safety concerns might diminish
the potential market for biosimilars, this situation might not be
economically efficient for any of the parties involved.
In addition to the concerns of higher development costs and
lower profit margins, the market for biologics is another concern.
Many biologic therapies treat life-threatening diseases. As such,
they target a smaller market than most small-molecule
compounds.' 8 Also, healthcare providers are less likely to utilize
price-fixing mechanisms for such therapies." 9 These factors make
a sudden and significant drop in price unlikely, even assuming
legislation authorizing approval is passed.
It is too early to speculate as to whether an economically
efficient equilibrium can be reached between supply and demand
for biosimilars in the U.S. market. Thus far, only one biosimilar
has been approved by the FDA. As previously mentioned,"0
Omnitrope, a human growth hormone biosimilar, was approved on
May 30, 2006, through an ANDA that essentially defined it as a
drug rather than a biologic."' While this approval process was
acceptable for Omnitrope because hGH is comparatively small (it
has 191 amino acids and weighs only 22 kilodaltons) and has a
relatively simple structure (only 4 helices), it will not be widely
at http://www.globalbusinessinsights.com/content/rbhc0187m.pdf (abstract
only).
106. National Association of Chain Drug Stores, Industry Facts-At-A-
Glance: Pharmaceutical Pricing,
http://www.nacds.org/wmspage.cfi?parm 1 =507#pharmpricing (last visited
Apr. 28, 2008).
107. MARCHANT, supra note 105.
108. Henry Grabowski et al., The Market for Follow-On Biologics: How Will
it Evolve?, 25 HEALTH AFF. 1291, 1294 (2006).
109. Id. at 1295.
110. See Omnitrope, supra note 70, and accompanying text.
111. Mark J. Belsey et al., Biosimilars: Initial Excitement Gives Way to
Reality, 5 NATURE REv. DRUG DISCOVERY 535, 535 (2006) available at
http://www.nature.com/nrd/journal/v5/n7/pdf/nrd2093.pdf.
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available. Omnitrope is marketed at 75% of the cost of the
original compound, 112 and the market reaction to the biosimilar
introduction has not yet been studied.
B. A European Model
Since the European Union (EU) passed regulations for
biosimilar approval in 2003,13 we can utilize market data from
Europe to predict some of the effects introduction of biosimilars
will have on the U.S. market. While the EU system allows for
approval of biologics under the regular generic approval process
(the equivalent of filing an ANDA with the FDA), it also allows
for an alternative route to approval, recognizing the improbability
of a true generic biologic."' To date, though, only two biosimilar
drugs have been approved through the latter route; thus, it is
premature to predict the market effects in the U.S. Nonetheless,
many believe that the head start biosimilars have acquired in
European markets will benefit generic companies with a strong
European presence, possibly to the detriment of American-based
generic manufacturers. 115 The European Generic Medicines
Association stated that because the EU developed a biosimilar
approval system first, it is set to become "the global centre for
R&D and production of this new generation of affordable, biotech
pharmaceuticals, giving the EU a huge competitive advantage over
other countries like the United States and Japan."" 6
Another problem with using European market data to predict the
ultimate effects that introduction of biosimilars will have on the
U.S. market is that many European countries have price-fixing
112. Roger & Mikhail, supra note 56, at 408.
113. The EU guidelines are enforced by the European Medicines Agency
(EMEA). See European Medicines Agency, About,
http://www.emea.europa.eu/htms/aboutus/emeaoverview.htm (last visited Apr.
28, 2008).
114. Follow-on Biologics: Hearing Before the S. Comm. on Health,
Education, Labor, and Pensions, 110th Cong. (2007) (statement of Nicolas
Rossignol, Administrator, European Commission Pharmaceutical Unit).
115. MARCHANT, supra note 105.
116. First Biosimilar Drug Gets EU Authorisation, EURACTIVE.COM, Apr.
21, 2006, http://www.euractiv.com/en/health/biosimilar-drug-gets-eu-market-
authorisation/article- 154524.
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mechanisms in place for medication." 7  If the brand-name drug
prices are fixed low enough, it could be difficult for the generic
manufacturers to make a profit since expenses for development of
biosimilars are much higher than for small-molecule generics.
The European biosimilar approval system differs from the
proposed U.S. legislation in several significant ways. First, market
exclusivity under the EU system is eight years, with the caveat that
a similar drug, though permitted to apply after eight years, cannot
actually enter the market for ten years. Second, the type and
amount of data required for each application varies on a case-by-
case basis. In essence, then, the European Medicines Agency's
(EMEA) disclosure requirements of demonstrated safety and
efficacy of a biosimilar are essentially product class-specific. A
biosimilar application could, therefore, range in specificity from
being almost on par with a generic application (merely showing
the properties of the proposed generic, with very limited non-
clinical/clinical studies), to being nearly as complete and specific
as a full, stand-alone application for a novel drug or formulation,
depending on which class of products it represents. "8 However,
we will have to wait several more years until we fully understand
the impact that these differences will have on the relative success
of the systems.
C. Other International Systems
In addition to the European market, India has gained a
substantial foothold in the market for biosimilars. The Indian
Food and Drug Control Administration is responsible for oversight
of pharmaceuticals, which include biosimilars. Three conditions
must be met before approval is issued for a typical biotech
product: (1) the Department of Biotechnology must approve
protocols of the animal toxicity studies used; (2) the Drug
Controller General of India must approve clinical trials and final
product for marketing; and (3) The Food and Drug Control
117. See Bruce Odessey, Officials See Slight Hope on Reversing Foreign
Drug Price Fixing, WASH. FILE, Apr. 27, 2004,
http://www.america.gov/st/washfile-
english/2004/April/20040427155048ebyessedo6.563967e-02.html.
118. MARCHANT, supra note 105.
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Administration must issue a manufacturing approval. All these
approvals can be completed within a year.
In contrast, biosimilar approval only requires clinical trials of
100 patients at an average cost of $100,000. At least seven
manufacturers are currently taking advantage of the biosimilar
market, though several are still in the planning stages. In May of
2007, Dr. Reddy's, an Indian generic drug manufacturer, it9
released Reditux, a biosimilar version of Rituxan, a monoclonal
antibody (MAb) treatment of Non-Hodgkin's Lymphoma. To date,
Reditux represents the only biosimilar MAb in the world.
However, because Dr. Reddy's used an entirely different process
of manufacture than is used for Rituxan, there has been no
resulting patent litigation. Reditux is priced 50% lower than
Rituxan, which generated global sales of $3 billion in 2006. Dr.
Reddy's plans to market Reditux in the United States as soon as
mechanisms are in place for FDA approval, which would
essentially exclude American generic manufacturers from
competing since the foreign competitor would have such a
significant head start.
There is less danger to American generic companies from China.
China, unlike India, has few generic "powerhouse" companies.
Additionally, while Indian companies like Dr Reddy's and
Ranbaxy can compete with the American companies as soon as an
FDA approval process is established, China has no such
companies poised with a similar advantage. For example, one of
the largest Chinese biotech companies, 3Sbio, generated only a
paltry $12 million marketing erythropoietin in 2006.
Three factors, however, make China ripe for generic expansion.
First, with China's lower per capita income, the expense of brand-
name biologics is often prohibitive. The three top-selling
119. Dr. Reddy's Laboratories Ltd., founded in 1984, had much of its initial
success in countries which did not recognize process patents. This allowed the
company to reverse-engineer drugs from the U.S. and Western Europe and sell
royalty-free versions of them in Russia and India. By the 1990s, the profits
made from these endeavors allowed the company to move into regulated
markets such as the U.S. Currently, Dr. Reddy's is the third-largest
pharmaceutical company in India with a yearly revenue of $1.5 billion and a
presence in over 100 countries across the globe. See generally Dr. Reddy's-
About Us, http://www.drreddys.com/coverview/aboutus.htm (last visited Apr.
28, 2008).
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biologics-Neupogen, Epogen, and Intron A-cost at least
$15,000, $10,000, and $22,000, respectively, per patient per
year.'20 Another popular biologic, Cerezyme, costs over $170,000
per patient per year. These prices make the products inaccessible
for many who need them. Second, the large population of China
compounds the problem of high prices. Third, the close proximity
of China to other Asian markets makes it likely that Chinese
generic manufacturers will expand in the near future.
It is possible, however, that with numerous recent high-profile
quality control scares surrounding imported products from
China,12 American patients and doctors will be unlikely to risk
prescribing or taking the imported biosimilar medication. This
could make it difficult for Chinese companies to compete
effectively in the American market regardless of whether they
have a head start.
D. Having Your Cake and Eating It Too: The Enablement Problem
The unpredictability of the behavior of biologic compounds
during production has consequences not only for production of a
true generic, but also for patentability. A biotechnology patentee
has the opportunity to deposit biological specimens to aid in the
required written disclosure of the invention, as it is sometimes
difficult for the written description to adequately illustrate the
nature of the invention,'22 but a biotechnology patent is still bound
by the same statutory requirements for patentability as any other
patent.
Among these patentability requirements is the requirement that
the specification of the patent "enable" an individual with skill in
120. Schultz Testimony, supra note 67.
121. Imported Chinese fish, seafood, toothpaste, toys, tires, and pet food
have all been found to have potentially dangerous flaws due to inadequate
quality control measures. See, e.g. Bush Tackles Scares Over Imports, BBC
NEWS, July 18, 2007, http://news.bbc.co.uk/2/hi/americas/6905372.stm.
122. "Biological material need not be deposited unless access to such
material is necessary for the satisfaction of the statutory requirements for
patentability under 35 U.S.C. 112. . . . Biological material need not be
deposited, inter alia, if it is known and readily available to the public or can be
made or isolated without undue experimentation." 37 C.F.R. § 1.802(b) (2007).
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the relevant art to make and use the invention. 2 3  Without
enablement, the quid pro quo of the U.S. patent system breaks
down; the patentee does not provide enough information to the
public to merit the embarrassment of a public monopoly.'24 As
summarized in United States v. Dubilier Condenser Corp.:
[the inventor] may keep his invention secret and
reap its fruits indefinitely. In consideration of its
disclosure and the consequent benefit to the
community, the patent is granted. . . . [U]pon
expiration of the [patent production] period, the
knowledge of the invention inures to the people,
who are thus enabled without restriction to practice
it and profit by its use. 25
For example, in Genentech, Inc. v. Novo Nordisk, the court
struck down a patent directed towards a method for producing a
protein of human growth hormone (hGH) amino acids, including
the step of cleaving a conjugate protein'26 through a method called
"cleavable fusion expression," even though the method was known
and used in similar processes.'27 The court held that just stating
that cleavable fusion expression was possible was insufficient to
enable one skilled in the art to practice the method. The court
reasoned:
Genentech's arguments, focused almost exclusively
on the level of skill in the art, ignore the essence of
123. 35 U.S.C. §112 (2006).
124. Letter from Thomas Jefferson to Isaac McPherson (Aug. 13, 1813), in
THE WRITINGS OF THOMAS JEFFERSON, at 335 (Andrew A. Lipscomb & Albert
Ellery Bergh eds., 1905), available at http://press-
pubs.uchicago.edu/founders/printdocuments/al 88s 12.html.
125. United States v. Dubilier Condenser Corp., 289 U.S. 178, 186-187
(1933).
126. A conjugate protein is one attached to the protein or peptide of interest,
often done so that the body can recognize the molecule. In order to purify a
sample of the protein of interest, however, the conjugate protein must be
detached or "cleaved" from it.
127. Genentech, Inc. v. Novo Nordisk, 108 F.3d 1361, 1363, 1368 (Fed. Cir.
1997).
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the enablement requirement. Patent protection is
granted in return for an enabling disclosure of an
invention, not for vague imitations of general ideas
that may or may not be workable. Tossing out the
mere germ of an idea does not constitute enabling
disclosure. While every aspect of a generic claim
certainly need not be carried out by an inventor, or
exemplified in the specification, reasonable detail
must be provided in order to enable members of the
public to understand and carry out the invention. 8
1. Impossibility of Replication-the Brand-Name Perspective
The essence of the arguments over biosimilars in both Congress
and the scientific community rests on the fact that the scientific
community cannot exactly duplicate biologic compounds, hence
the use of the new term "biosimilar" or "follow-on biologic" in
place of"biogeneric."' 29 The pharmaceutical companies that lobby
against approval of biosimilars have gone to great lengths to
demonstrate the impossibility of replicating their work exactly
with the current technological limitations. 3 Executives from
large pharmaceutical corporations such as Novartis, Johnson &
Johnson, and Pfizer have testified before congressional committees
and cited public health and safety as a reason to halt the approval
of an expedited approval process for biosimilars.'' They claim
that there is no possible way to exactly and safely copy their
results.'32 Even with the information provided in their own patent
disclosures, including deposited biological samples, the end
product is unpredictable.'33  Indeed, the deposited biological
samples rarely include samples of their cell lines, but rather just
the end product biologic. This gives no aid to anyone attempting
128. Id. at 1366.
129. See supra note 60 and accompanying text.
130. See Hobbs, supra note 80.
131. See, e.g., Follow-on Biologics: Hearing Before the S. Comm. on Health,
Education, Labor, and Pensions, 110th Cong. (2007).
132. Id.
133. See Hancock Testimony, supra note 54 and accompanying text.
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to replicate the patent-holder's process of manufacture-a process
which is a prerequisite to achieving the desired biologic. 4
2. Implications for Patentability
If this is indeed the case, then brand-name manufacturers have
made a prima facie case against their own patent's enforceability
due to nonenablement. Even with samples of the compounds,
detailed instructions on the process of manufacture (in some
cases), and intimate scientific knowledge of the mechanism of use
of the compound and the human body's reaction to it developed
over years of study, the results are still impossible to duplicate,
even by one highly skilled in the relevant art. It is in the nature of
biologic compounds that the results are unpredictable. And that
detection of variation is in some cases impossible until it interacts,
often deleteriously, with the patient. '35
However, the fact that it is impossible for the inventor to enable
the use of the invention through the written description does not
negate the requirement that enablement exist for the subject matter
to be patentable. If enablement is itself impossible, then trade
secret protection might be more advisable than patent protection,
as reverse engineering such a complicated process is highly
improbable.
3. Trade Secret Protection as an Alternative
Trade secret law is particularly valuable in situations where the
product is valuable, the manufacturer desires protection for longer
than the statutory patent term, and there is little likelihood that the
product will be copied.'36  However, a patented invention is
protected against not only literal infringement, but also under the
doctrine of equivalents,'37 which has no counterpart in trade secret
law. Here, this would mean that changing one or two unimportant
134. See supra notes 59-60 and accompanying text.
135. See supra notes 50-51 and accompanying text.
136. See generally Michael Risch, Why Do We Have Trade Secrets?, 11
MARQ. INTELL. PROP. L. REV. 1 (2007).
137. See 5 DONALD S. CHISUM, CHISUM ON PATENTS, § 16.02[1][a][ii]
(1998).
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steps in the process of manufacture would still infringe the
patented process, while a small change would overcome trade
secret protection.
While it might not seem that allowing a patentee to obtain and
enforce a patent over a biologic is in line with the notion of equity
inherent in the U.S. patent system, where no one else can make use
of the patentee's invention, such patents have been repeatedly
upheld without any question as to their validity under 35 U.S.C. §
112.
One of the most recent cases to underscore the strength of the
validity of biotechnology patents was Amgen, Inc. v. Hoechst
Marion Roussel, Inc. 38 In this case, the patentee sought a
declaratory judgment that the defendant infringed five of its
patents covering the biologic erythropoietin (EPO).' 39  In an
extended discussion regarding enablement of the claims, after
which the court eventually declared the patents invalid, the nature
of biologics and impossibility of enablement were not mentioned.
Rather, the court said that the claims were not enabled because the
patentee did not disclose how to deposit kidney tumor cells. 4 0 The
court was silent regarding the fact that even if the exact process
had been disclosed and duplicated,-the outcome would not have
been identical. Even while holding that the patent claims in
question in this case were not enabled, the court strengthened
biotechnology patents as a whole.
There may be a public policy explanation behind the obvious
missing pieces in opinions such as Amgen. While the United
States is still a world leader in pharmaceutical development,
thanks in large part to price-fixing in Europe and Japan, it is
lagging in the field of biosimilars. 4' The EU, Japan, China, and
India, all have regulations allowing for the approval of biosimilars.
An innovative biosimilar segment of the U.S. economy could help
ameliorate some of the growing concern over the cost and
regulation of healthcare in the U.S. It could reinvigorate the
biotechnology sector, and, by extension, the foundering
138. Amgen, Inc. v. Hoechst Marion Roussel, Inc., 457 F.3d 1293 (Fed. Cir.
2006).
139. Id. at 1295.
140. Id. at 1307.
141. See supra Section III.
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economy.14
2
In order to promote continued research and development in
biotechnology, however, American patents must be strong enough
to protect the ideas they generate. If foreign patents are stronger,
or if there are questions about whether biotechnology patents will
be interpreted consistently through our patent law, there is little
incentive for inventors to file in the U.S. Protecting innovation is
crucial for industry growth.
Recently, the U.S. House of Representatives passed H.R. 1908,
the Patent Reform Act of 2007.143 Many of its provisions, such as
more accessible reexamination procedures, post-patent review, and
third-party prior art submissions are directly aimed at
strengthening U.S. patents. 144  According to the Patent Reform
Act's sponsor, Representative Howard Berman stated:
[T]here should be no question that the U.S. patent
system produces high quality patents. Since
questions have been raised about whether this is the
case, the responsibility of Congress is to take a
close look at the functioning of the patent system.
High patent quality is essential to continued
innovation. 145
This sentiment is shared by many, as the passage of the bill in
Congress demonstrates. It is also likely behind the reluctance of
the courts and the legislature to address the problem of the lack of
enablement in biologic patent specifications. While the goals
behind the actions-improving the international reputation of
American patents, boosting the biotechnology sector, improving
healthcare, decreasing the national debt-are admirable, upholding
patents that do not meet the statutory requirements for patentability
142. Healthcare spending comprised 16 percent of the gross domestic
product in 2004. More money was spent per capita that same year on healthcare
than on food. For a complete discussion, see JULIUS RICHMOND AND RASHI
FEIN, THE HEALTH CARE MESS: How WE GOT INTO IT, AND WHAT IT WILL
TAKE TO GET OUT (2005).
143. Patent Reform Act of 2007, H.R. 1908, 110th Cong. (2007).
144. 153 CONG. REC. E773 (daily ed. Apr. 18, 2007) (statement of Rep.
Berman).
145. Id. at E775.
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is confusing and ultimately harmful to U.S. patent law.
E. Patentability Revisited-the Novelty Requirement
Another statutory requirement of patentability is that the claimed
invention be "novel."' 46  In order to be novel, at least one
limitation of the claimed invention must be disclosed or
"anticipated" by a prior art reference. Prior art can include a
patent, published patent application, journal article, or other
reference listed in 35 U.S.C. § 102, assuming that the requisite
time constraints are met. The purpose of the novelty requirement
is to prevent the issuance of patents covering material in the public
domain. If an inventor does not disclose something that was
previously unknown to a person of ordinary skill in the relevant
art, then he is not entitled to monopoly privileges. As Justice
O'Connor has said, "[t]he novelty and nonobviousness
requirements of patentability embody a congressional
understanding, implicit in the Patent Clause itself, that free
exploitation of ideas will be the rule, to which the protection of a
federal patent is the exception."' 47
In Diamond v. Chakrabarty,'48 the Supreme Court opened the
proverbial floodgates to a deluge of biotechnology innovation and
litigation when it extended the scope of statutorily patentable
inventions to cover the biotech sector. In holding that a
genetically engineered bacterium capable of breaking down crude
oil was patentable, the Court dispensed with the notion that a
living organism could not be patented.'49 The closely-related idea,
however, that a naturally-occurring living organism is not
patentable, was endorsed by the Court's opinion. 5 ' As the court
146. "Whoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor, subject to the conditions and requirements
of this title." 35 U.S.C. § 101 (2006) (emphasis added).
147. Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 151
(1989).
148. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
149. Id. at315-16.
150. A live, human-made micro-organism is patentable subject matter under
35 U.S.C. § 101. Respondent's micro-organism constitutes a "manufacture" or
"composition of matter" within that statute. Id. at 310.
2008]
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explained, a naturally-occurring organism is not novel. Just as
discovery of a scientific principle or mathematical formula is not
patentable, 15' neither should a hormone or protein complex found
in vivo be. It may have taken considerable work for Einstein to
perfect the famous E=mc2 equation. It may have taken mental
processes that few others in the world could have accomplished,
and the result was unmistakably useful. These facts, however, do
not make the equation patentable subject matter. It was merely
discovered, not truly invented. '52
The same rationale applies to most biologic therapies. Deducing
the steps required to purify and produce insulin, for example, took
considerable work by some of the top scientists in the field.
Indeed, work began on purification of human insulin for
therapeutic purposes as early as 1963, but it was 1982 before Eli
Lilly successfully obtained approval to market its insulin
therapy. 15 3 The resulting product is unmistakably useful, even life-
saving. These facts, however, and the costs expended in research
and development by pharmaceutical companies, do not make
insulin patentable subject matter. It is a naturally-occurring
molecule, and therefore not "invented."
F. Taking Intellectual Property-the Constitutional Issue
The brand-name companies counter these arguments by
claiming that it is an unconstitutional taking without just
compensation for the FDA to utilize knowledge garnered from
their applications and clinical trials to make decisions regarding
generic drugs or biologics. Genentech, a large brand-name
company, recently filed a citizen petition with the FDA asserting
that the agency should not even issue an opinion in the debate over
data requirements for biosimilar applications, since they would
have the benefit of knowledge garnered from patentees such as
Genentech.'54  A "guidance document" issued by the FDA
151. Traditionally, discoveries in three areas do not qualify for an exclusive
right-natural laws, phenomena of nature, and abstract principles. See Diamond
v. Diehr, 450 U.S. 175, 185 (1981).
152. Id.
153. MICHAEL BLIss, THE DISCOVERY OF INSULIN 155 (1982).
154. See Schultz Testimony, supra note 67.
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represents the agency's current thinking on a given topic.
Preparing such a document necessitates using the agency's
cumulative knowledge based on all prior approvals and
applications, though not the actual data itself.'55 The Generic
Pharmaceutical Association objected to the petition and is having a
thorough constitutional analysis of the issue prepared for
distribution to the interested parties.156
Congress needs to address the issues of enablement, novelty,
and takings in any bill covering biosimilars. If these issues are not
addressed, then the confusion and the friction between the
industry, the FDA, and the judicial system will continue to build.
While it would take time and litigation to sort out all the
contradictions that have emerged even if the bill were passed
today, the longer the legislature delays, the more tangled the
problem becomes and the more time-consuming the solutions.
V. CONCLUSION
Biologics are the ultimate therapies: unlike traditional drugs,
which are substances foreign to the human body that change the
way it naturally functions, they are the missing parts of the body
itself. For example, instead of taking a drug that affects the cells
in the endocrine system and squeezes more hGH out of the
pituitary gland, now the hGH itself can simply be supplied. These
therapies are the frontier of medicine, and the law must be
extended to protect them.
Now that the United States is years behind its foreign
counterparts in the biosimilar industry, any proposed legislation
attempting to ameliorate the deficiency is welcome, if only to
impress upon Congress the urgency of the situation. There is an
unmistakable need for an expedited approval process in order to
provide incentives for competition in the biologic drug industry.
This type of competition, when seen in the small-molecule
pharmaceutical sector, was simultaneously responsible for saving
consumers billions of dollars and promoting increased spending on
research and development for innovative treatments. However,
using a Hatch-Waxman approach while requiring almost as many
155. Id.
156. Id.
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clinical trials as for an innovative drug is not a workable solution.
Large pharmaceutical corporations and consumers may benefit,
but there may not be enough profit incentive for the follow-on
biologic industry to compete.
The existing patent law should also be considered during the
debate over biosimilar legislation. If large pharmaceutical
companies are allowed to claim that concern for the public safety
and welfare should bar expedited approval processes (and, hence,
biosimilars), their patents covering the material should be invalid
for lack of enablement. Invalidating these patents would have the
dual advantage of advancing public safety concerns by requiring
the equivalent of an NDA or BLA from any manufacturer,
innovative or follow-on, and of providing an incentive for
competition in the biologic sector by removing the hurdle of
proving invalidity through costly litigation. However, without any
patent protection available for biologics, Congress understandably
worries about losing pharmaceutical business in the United States.
Ultimately, the Hatch-Waxman Act can provide a working
framework for expedited biosimilar approval. Using it as a mold
gives us the advantage of almost a quarter of a century of
experience and troubleshooting. Going beyond that, however, and
attempting to literally copy and paste the language of the Hatch-
Waxman Act into the Biologics Act will not guarantee the same
results that the former produced for small-molecule compounds in
1984.
A. Taylor Corbitt
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